Aptuit

Aptuit is a company that provides comprehensive research and development services to enhance the efficiency of drug discovery and development across various therapeutic areas, using advanced technologies and collaborative partnerships. Founded in 2004 and headquartered in Greenwich, US, Aptuit specializes in drug development and research services. In July 2017, Evotec agreed to acquire Aptuit for USD 300. 00 mn, marking a strategic expansion.

The company has completed three deals to date, with its most recent deal occurring on July 30, 2017. The acquisition of Aptuit is part of Evotec's broader strategy to enhance its R&D capabilities. The founder's specific history is not detailed, but the company has seen significant changes through this acquisition process. Aptuit specializes in research and development (R&D) services aimed at advancing drug discovery and development processes across various therapeutic areas.

The company's core offerings include high-value pipeline co-creation partnerships, contract research organization (CRO) and contract development and manufacturing organization (CDMO) services. These services are designed to enhance the efficiency and effectiveness of R&D programs, from disease understanding to investigational new drug (IND) applications and beyond. Aptuit leverages proprietary, AI-powered R&D platforms to provide insights that drive better disease understanding and human relevance, ultimately leading to innovative therapeutics. The company serves a diverse client base, including pharmaceutical and biotechnology companies across global markets including North America, Europe, and Asia, focusing on unmet medical needs across various diseases and conditions.

Aptuit generates revenue through the establishment of collaborative partnerships and service agreements with pharmaceutical and biotechnology companies. Transactions are structured around project-based agreements, where clients engage Aptuit for its specialized R&D services, often involving milestones and deliverables tied to specific project phases. The company’s revenue model includes both upfront payments and success-based milestones, which incentivize performance and align client interests with Aptuit's capabilities. Aptuit plans to utilize the recent acquisition by Evotec to enhance its product offerings and expand its market presence.

The acquisition deal occurred in July 2017, and the integration of Aptuit's capabilities is expected to lead to new product developments. The company aims to expand into new geographic regions, specifically targeting additional markets in Europe and Asia by 2025, leveraging Evotec's existing infrastructure. The funding from the acquisition, amounting to USD 300. 00 mn, will support these initiatives and facilitate the growth of its R&D capabilities.